Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Benzocaine, eugenol for toothache OTC "feedback" meeting with NDMA set for June 25.

This article was originally published in The Tan Sheet

Executive Summary

BENZOCAINE, EUGENOL FOR TOOTHACHE OTC "FEEDBACK" MEETING TO BE HELD at FDA June 25 with the Nonprescription Drug Manufacturers Association. In an April 29 letter to FDA, the trade association asked the agency for "feedback" on the effectiveness of both ingredients for the relief of toothache. "Our concerns to discuss at the meeting include the status of benzocaine as an active ingredient for the temporary relief of toothache when the Final Monograph for Oral Health Care Products is established," the letter states. The safety of the ingredients is not at issue.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel